Results 31 to 40 of about 854 (146)

Comparison of effectiveness and safety of lasmiditan and CGRP-antagonists for the acute treatment of migraine in adults: systematic review and network meta-analysis of randomised trials [PDF]

The Journal of Headache and Pain
Objective To compare the outcomes associated with the use of lasmiditan, rimegepant, ubrogepant, and zavegepant for the acute management of migraine headaches.
Xinxin Deng, Liying Zhou, Cui Liang, Xue Shang, Xu Hui, Wendi Liu, Shanshan Liang, Yongsheng Wang, Meng Xu, Kangle Guo, Kehu Yang, Xiuxia Li   +11 more
doaj   +2 more sources

Acute and preventive treatment of menstrual migraine: a meta-analysis [PDF]

The Journal of Headache and Pain
Background and objectives About a quarter of migraine cases among women have menstrual migraine (MM), which is usually more severe, longer lasting, and less responsive to treatment than typical migraine. Randomized controlled trials (RCTs) have evaluated
Cindy Ciat-Wuah Khoo, Chan-Cheng Liu, Michael Lu, Yu-Chen Huang, Hsing-Yu Weng   +4 more
doaj   +2 more sources

Novel optimization of multi-mechanistic approaches for the acute treatment of a migraine attack: A review. [PDF]

Headache
Abstract Objective To highlight key factors required to optimize multi‐mechanistic approaches with oral combination treatments for the acute management of a migraine attack. Background Given the complex multi‐factorial nature of migraine, combining treatments with different mechanisms of action should improve outcomes compared to monotherapies, but ...
Silberstein S, Rapoport AM.
europepmc   +2 more sources

Lasmiditan inhibits calcitonin gene-related peptide release in the rodent trigeminovascular system [PDF]

, 2020
Migraine headache pathophysiology involves trigeminovascular system activation, calcitonin gene-related peptide (CGRP) release, and dysfunctional nociceptive transmission.
Chan, K.Y. (Kayi), Rubio-Beltrán, A.E. (Eloísa), Garrelds, I.M. (Ingrid), Johnson, K.W., Maassen van den Brink, A. (Antoinette), Villalon, C.M. (Carlos), Haanes, KA, Danser, A.H.J. (Jan), Labastida-Ramirez, A. (Alejandro), Carlos M. Villalón, Van den Berg - Garrelds, Ingrid; id_orcid, Antoinette MaassenVanDenBrink, Haanes, Kristian A, Eloísa Rubio-Beltrán, Maassen van den Brink, Antoinette, Haanes, Kristian A., Chan, Kayi Y, Haanes, Kristian, Chan, Ka yi, Chan, Kayi Y., Alejandro Labastida-Ramírez, Villalón, Carlos M., Rubio-Beltrán, Eloísa; id_orcid, Villalón, Carlos M, Ingrid M. Garrelds, Labastida Ramirez, Alejandro, MaassenVanDenBrink, Antoinette, Labastida-Ramírez, Alejandro; id_orcid, Danser, AHJ, Johnson, KW, Johnson, Kirk W., Kirk W. Johnson, Kristian A. Haanes, Rubio-Beltrán, Eloísa, Alexander H.J. Danser, Garrelds, Ingrid M, Kayi Y. Chan, Villalon, CM, Garrelds, Ingrid M., Danser, Alexander H.J., Danser, Alexander H J, Labastida-Ramírez, Alejandro, Rubio Beltran, Amada, Johnson, Kirk W   +43 more
core   +5 more sources

Optimal dosing of lasmiditan in the management of acute migraine attack: A systematic review and meta-analysis

Annals of Indian Academy of Neurology, 2021
Background: The current target of migraine treatment is focused on Triptans. Lasmiditan, a non-vasoconstrictive and highly selective 5HT1F receptor agonist is a novel therapeutic discovery for migraine for patients with cardiovascular (CV) risk factors ...
Roopa Satyanarayan Basutkar, Chris Elizabeth Vinod, Shruthi Jaya Saju, Bhavya Chebrolu, Sivasankaran Ponnusankar   +4 more
doaj   +1 more source

receptor agonist lasmiditan [PDF]

, 2019
Background and Purpose: Triptans are 5-HT1B/1D receptor agonists (that also display 5-HT1F receptor affinity) with antimigraine action, contraindicated in patients with coronary artery disease due to their vasoconstrictor properties.
Antoinette MaassenVanDenBrink, Maassen van den Brink, Antoinette, Villalón, Carlos M., Alejandro Labastida‐Ramírez, A.H. Jan Danser, Bogers, Ad J.J.C., Labastida Ramirez, Alejandro, Labastida-Ramírez, Alejandro; id_orcid, Johnson, Kirk W., Kirk W. Johnson, Villalón, CM, Zanelli, Eric, Kovalchin, Joseph, Rubio-Beltrán, Eloísa, Peter B. Senese, Johnson, K, Gralinski, Michael R, Eloísa Rubio‐Beltrán, van den Bogaerdt, Antoon, Labastida-Ramírez, Alejandro, Rubio Beltran, Amada, Bogaerdt, Antoon, Senese, Peter B., Ad J.J.C. Bogers, Senese, Peter B, Michael R. Gralinski, Johnson, Kirk W, Carlos M. Villalón, Zanelli, E, Gralinski, Michael R., Danser, A H Jan, Haanes, Kristian A, Haanes, Kristian A., Haanes, Kristian, Joseph Kovalchin, Rubio-Beltrán, Eloísa; id_orcid, Villalón, Carlos M, MaassenVanDenBrink, Antoinette, Danser, A. H.Jan, Eric Zanelli, Kristian A. Haanes, Meeus, L, Antoon van den Bogaerdt, Senese, PB, Bogers, Ad; id_orcid, Gralinski, MR, Laurent Meeus, Danser, Jan, Bogers, Ad J J C, Meeus, Laurent, Kovalchin, J   +50 more
core   +2 more sources

Integrating gepants into clinical practice for the acute treatment of migraine. [PDF]

Headache
Abstract Objective To assess the role of small‐molecule calcitonin gene–related peptide receptor antagonists (gepants) in the acute treatment of migraine, particularly in relation to triptan treatments. Background Triptans have established efficacy and are widely prescribed for the acute treatment of migraine.
Lipton RB, Dodick DW, Davis L, Nahas SJ, Goadsby PJ.   +4 more
europepmc   +2 more sources

Safety profile of lasmiditan in patients with migraine in an Asian population

, 2022
MONONOFU, a multicenter, randomized, double-blind, placebo-controlled phase 2 study of Japanese patients with migraine, was pivotal for lasmiditan approval in Japan.
Yasuhiko Matsumori (11329325), Mika Komori (114112), Yuka Tanji (12913965), Koichi Hirata (52794), Rashna Khanna (7327265), Akichika Ozeki (10163261)   +5 more
core   +1 more source

Awareness and Prescribing Patterns of Acute and Preventive Migraine Medications Among General Practitioners: The Kawasaki Medical Association Study [PDF]

Pain Res Manag
Aim In Japan, the introduction of anti‐calcitonin gene‐related peptide (CGRP) monoclonal antibodies and the 5‐HT1F receptor agonist lasmiditan has transformed migraine treatment. However, medical consultation and prescription rates for migraine remain low.
Akiyama H, Ono H, Komine Y, Nakano Y, Yamano Y.   +4 more
europepmc   +2 more sources

The Neuropsychiatric Safety Profile of Lasmiditan: A Comparative Disproportionality Analysis with Triptans

, 2023
International audienceMigraine constitutes the world's second-leading cause of disability. Triptans, as serotonin 5-HT1B/1D receptor agonists, remain the first-line treatment, despite discouraged use in individuals at high cardiovascular risk. Lasmiditan,
Alexandre O. Gérard, Merino, Diane, van Obberghen, Elise, Gérard, Alexandre, Alexandre Destere, Milou-Daniel Drici, Destere, Alexandre, Michel Lanteri-Minet, Diane Merino, Elise K. Van Obberghen, Lanteri-Minet, Michel, Drici, Milou-Daniel   +11 more
core   +1 more source